RS55804B1 - Testovi za adrenomedulin i metodi za određivanje zrelog adrenomedulina - Google Patents

Testovi za adrenomedulin i metodi za određivanje zrelog adrenomedulina

Info

Publication number: RS55804B1
Authority: RS; Serbia
Prior art keywords: adrenomedullin; assays; methods; determining mature; determining
Prior art date: 2011-11-16

Application number

RS20170258A

Other languages

English (en)

Inventor

Andreas Bergmann

Original Assignee

Sphingotec Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-11-16

Filing date

2012-11-16

Publication date

2017-08-31

2012-11-16 Application filed by Sphingotec Gmbh filed Critical Sphingotec Gmbh

2017-08-31 Publication of RS55804B1 publication Critical patent/RS55804B1/sr

Links

102000004379 Adrenomedullin Human genes 0.000 title 2
101800004616 Adrenomedullin Proteins 0.000 title 2
ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 title 2
238000003556 assay Methods 0.000 title 1
238000000034 method Methods 0.000 title 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Marine Sciences & Fisheries (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)

RS20170258A 2011-11-16 2012-11-16 Testovi za adrenomedulin i metodi za određivanje zrelog adrenomedulina RS55804B1 (sr)

Applications Claiming Priority (13)

Application Number	Priority Date	Filing Date	Title
EP11189452		2011-11-16
EP11189449		2011-11-16
EP11189447		2011-11-16
EP11189448		2011-11-16
EP11189450		2011-11-16
EP12160016		2012-03-16
EP12160015		2012-03-16
EP12160018		2012-03-16
EP12160017		2012-03-16
EP12160014		2012-03-16
EP12186449		2012-09-27
PCT/EP2012/072928 WO2013072509A1 (en)	2011-11-16	2012-11-16	Adrenomedullin assays and methods for determining mature adrenomedullin
EP12791143.6A EP2780717B1 (en)	2011-11-16	2012-11-16	Adrenomedullin assays and methods for determining mature adrenomedullin

Publications (1)

Publication Number	Publication Date
RS55804B1 true RS55804B1 (sr)	2017-08-31

Family

ID=47148677

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
RS20170258A RS55804B1 (sr)	2011-11-16	2012-11-16	Testovi za adrenomedulin i metodi za određivanje zrelog adrenomedulina

Country Status (16)

Country	Link
US (3)	US9304127B2 (sr)
EP (1)	EP2780717B1 (sr)
JP (1)	JP6336911B2 (sr)
CN (1)	CN104067130B (sr)
DK (1)	DK2780717T3 (sr)
ES (1)	ES2617211T3 (sr)
HK (1)	HK1202624A1 (sr)
HR (1)	HRP20170427T1 (sr)
HU (1)	HUE032648T2 (sr)
MY (5)	MY174877A (sr)
PL (1)	PL2780717T3 (sr)
PT (1)	PT2780717T (sr)
RS (1)	RS55804B1 (sr)
RU (1)	RU2657517C2 (sr)
SI (1)	SI2780717T1 (sr)
WO (1)	WO2013072509A1 (sr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2780371T (pt)	2011-11-16	2019-01-30	Adrenomed Ag	Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica
NZ624873A (en)	2011-11-16	2016-07-29	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
JP6224608B2 (ja)	2011-11-16	2017-11-01	アドレノメトアクチェンゲゼルシャフト	血液循環を安定化させるための、患者の急性疾患又は急性病態の治療法における使用に向けた、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
KR101548284B1 (ko) *	2014-05-23	2015-08-28	주식회사 나노엔텍	신규한 시료 내 검출대상물의 검출방법 및 그를 이용한 검출키트
EP3380845A1 (en) *	2015-11-27	2018-10-03	B.R.A.H.M.S GmbH	MR-proADM AS MARKER FOR THE EXTRACELLULAR VOLUME STATUS OF A SUBJECT
WO2018029213A1 (en) *	2016-08-09	2018-02-15	B.R.A.H.M.S Gmbh	Histones and/or proadm as markers indicating organ dysfunction
EP3309550A1 (en) *	2016-10-12	2018-04-18	sphingotec GmbH	Method for the detection of apolipoprotein e4
WO2018109228A1 (en) *	2016-12-16	2018-06-21	Adrenomed Ag	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
JP6862963B2 (ja) *	2017-03-17	2021-04-21	東ソー株式会社	ペプチドの吸着抑制剤
JP7270912B2 (ja) *	2017-05-22	2023-05-11	東ソー株式会社	アドレノメデュリン濃度変動による予後予測の情報提供方法及びその試薬
CN111065922A (zh) *	2017-09-13	2020-04-24	B.R.A.H.M.S有限公司	肾上腺髓质素原作为危重病患者的肾脏替代治疗的指标
WO2019057992A2 (en) *	2017-09-25	2019-03-28	Adrenomed Ag	ANTI-ADRENOMEDULIN (ADM) BINDER FOR USE IN TREATING OR PREVENTING THE SYMPTOMS OF A DISEASE
WO2019077082A1 (en)	2017-10-18	2019-04-25	Adrenomed Ag	SURVEILLANCE OF THERAPY UNDER TREATMENT WITH ANTI-ADRENOMEDULIN BINDER (ADM)
KR20200135947A (ko) *	2018-02-08	2020-12-04	스핑고텍 게엠베하	치매의 진단 및/또는 예측을 위한 아드레노메둘린 (adm) 및 치매의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 결합제
CN111770935A (zh) *	2018-02-27	2020-10-13	株式会社岛津制作所	特异性识别APP669-x的N末端的抗体及免疫测定法
WO2019167128A1 (ja) *	2018-02-27	2019-09-06	株式会社島津製作所	サンドイッチ型免疫測定法
EP3608673A1 (en) *	2018-08-08	2020-02-12	B.R.A.H.M.S GmbH	Pro-adm for prognosing the risk of a medical condition requiring hospitalization in patients with symptoms of infectious disease
CN113597429A (zh) *	2019-03-01	2021-11-02	株式会社岛津制作所	App669-711测定方法及测定用试剂盒
CN110470771B (zh) *	2019-09-05	2021-06-01	清华大学	一种评价转基因植物食用安全性的方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en)	1988-08-01	1993-03-04	Ciba Corning Diagnostics Corp.	Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
EP0463151B1 (en)	1990-01-12	1996-06-12	Cell Genesys, Inc.	Generation of xenogeneic antibodies
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
AU665190B2 (en)	1990-07-10	1995-12-21	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
AU3328493A (en)	1991-12-17	1993-07-19	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
JP2774769B2 (ja) *	1993-04-26	1998-07-09	賢治寒川	アドレノメデュリン
CA2229741C (en)	1995-08-18	2012-05-08	The Government Of The United States Of America	Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology
CA2242308A1 (en)	1997-12-08	1999-06-08	Smithkline Beecham Laboratoires Pharmaceutiques	Novel compounds
DE19847690A1 (de)	1998-10-15	2000-04-20	Brahms Diagnostica Gmbh	Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen
US6818418B1 (en)	1998-12-10	2004-11-16	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
PT1214600E (pt)	1999-09-10	2006-05-31	Us Gov Health & Human Serv	Determinacao de proteinas de ligacao a adrenomedulina
ATE458199T1 (de)	2001-05-04	2010-03-15	Biosite Inc	Diagnostische marker der akuten koronaren syndrome und ihre verwendungen
RU2209071C2 (ru) *	2001-08-08	2003-07-27	Ростовский НИИ акушерства и педиатрии	Способ лечения сепсиса у детей
BR0212256A (pt)	2001-08-30	2004-08-31	Biorexis Pharmaceutical Corp	Proteìnas de fusão de transferrina modificadas
US6864237B2 (en)	2002-05-17	2005-03-08	Ping Wang	Treatment of shock using adrenomedullin and adrenomedullin binding protein-1
CA2488558C (en)	2002-06-07	2013-08-20	Dyax Corp.	Prevention and reduction of blood loss
DE10316583A1 (de) *	2003-04-10	2004-10-28	B.R.A.H.M.S Aktiengesellschaft	Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
US20070082363A1 (en)	2003-04-25	2007-04-12	Lydie Bougueleret	Secreted polypeptide species reduced cardiovascular disorders
US6884781B2 (en)	2003-05-16	2005-04-26	Ping Wang	Treatment of shock using adrenomedullin binding protein-1
WO2005033327A2 (en) *	2003-09-29	2005-04-14	Biosite Incorporated	Methods and compositions for the diagnosis of sepsis
EP1675878A2 (en)	2003-10-24	2006-07-05	Avidia, Inc.	Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en)	2004-02-23	2010-02-04	Anaphore, Inc.	Tetranectin Trimerizing Polypeptides
WO2006027147A2 (en)	2004-09-09	2006-03-16	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr)
CA2580881A1 (en)	2004-09-21	2006-03-30	Nascacell Technologies Ag	Use of microproteins as tryptase inhibitors
JP4976412B2 (ja)	2005-12-01	2012-07-18	ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー	エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
US7993832B2 (en) *	2006-08-14	2011-08-09	Xdx, Inc.	Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
ES2373832T3 (es)	2007-12-19	2012-02-09	Affibody Ab	Polipéptido derivado de proteína a y capaz de unirse a pdgf.
KR101698362B1 (ko)	2008-11-03	2017-01-20	몰리큘라 파트너스 아게	Ｖｅｇｆ－ａ 수용체 상호작용을 억제하는 결합 단백질
NZ598351A (en)	2009-08-27	2014-08-29	Covagen Ag	Il-17 binding compounds and medical uses thereof
BR112012014194A2 (pt)	2009-12-14	2017-01-10	Scil Proteins Gmbh	um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos
DE102010040035A1 (de)	2010-03-04	2011-09-08	Robert Bosch Gmbh	Verbesserungen der Rückwärts-Analyse zur Bestimmung von Fehlermaskierungsfaktoren
PL2580236T3 (pl)	2010-06-08	2019-09-30	Pieris Pharmaceuticals Gmbh	Muteiny lipokaliny łez wiążące IL-4 R alfa
FR2964103B1 (fr) *	2010-08-30	2018-11-23	Universite D'aix-Marseille	Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament

2012
- 2012-11-16 SI SI201230877A patent/SI2780717T1/sl unknown
- 2012-11-16 EP EP12791143.6A patent/EP2780717B1/en active Active
- 2012-11-16 MY MYPI2014001420A patent/MY174877A/en unknown
- 2012-11-16 PL PL12791143T patent/PL2780717T3/pl unknown
- 2012-11-16 JP JP2014541693A patent/JP6336911B2/ja active Active
- 2012-11-16 ES ES12791143.6T patent/ES2617211T3/es active Active
- 2012-11-16 DK DK12791143.6T patent/DK2780717T3/en active
- 2012-11-16 MY MYPI2014001418A patent/MY178654A/en unknown
- 2012-11-16 MY MYPI2014001421A patent/MY175997A/en unknown
- 2012-11-16 HU HUE12791143A patent/HUE032648T2/en unknown
- 2012-11-16 US US13/679,294 patent/US9304127B2/en active Active
- 2012-11-16 RS RS20170258A patent/RS55804B1/sr unknown
- 2012-11-16 CN CN201280066354.5A patent/CN104067130B/zh active Active
- 2012-11-16 MY MYPI2014001422A patent/MY192113A/en unknown
- 2012-11-16 RU RU2014123987A patent/RU2657517C2/ru active
- 2012-11-16 WO PCT/EP2012/072928 patent/WO2013072509A1/en active Application Filing
- 2012-11-16 PT PT127911436T patent/PT2780717T/pt unknown
- 2012-11-16 US US13/679,281 patent/US9140696B2/en active Active
- 2012-11-16 MY MYPI2014001423A patent/MY174894A/en unknown
- 2012-11-16 US US14/358,147 patent/US9535060B2/en active Active
2015
- 2015-03-24 HK HK15102988.3A patent/HK1202624A1/xx unknown
2017
- 2017-03-16 HR HRP20170427TT patent/HRP20170427T1/hr unknown

Also Published As

Publication number	Publication date
CN104067130B (zh)	2017-02-22
EP2780717A1 (en)	2014-09-24
RU2014123987A (ru)	2015-12-27
PL2780717T3 (pl)	2017-06-30
MY174877A (en)	2020-05-20
US20130195874A1 (en)	2013-08-01
MY192113A (en)	2022-07-28
JP6336911B2 (ja)	2018-06-06
HK1202624A1 (en)	2015-10-02
HRP20170427T1 (hr)	2017-06-16
JP2014533827A (ja)	2014-12-15
EP2780717B1 (en)	2016-12-21
US20140322824A1 (en)	2014-10-30
MY178654A (en)	2020-10-20
DK2780717T3 (en)	2017-02-13
US9535060B2 (en)	2017-01-03
PT2780717T (pt)	2017-02-16
MY175997A (en)	2020-07-20
WO2013072509A1 (en)	2013-05-23
SI2780717T1 (sl)	2017-05-31
CN104067130A (zh)	2014-09-24
US20130195875A1 (en)	2013-08-01
RU2657517C2 (ru)	2018-06-14
US9140696B2 (en)	2015-09-22
HUE032648T2 (en)	2017-10-30
ES2617211T3 (es)	2017-06-15
MY174894A (en)	2020-05-20
US9304127B2 (en)	2016-04-05

Publication	Publication Date	Title
HK1202624A1 (en)	2015-10-02	Adrenomedullin assays and methods for determining mature adrenomedullin
HRP20180640T1 (hr)	2018-06-01	Anti-b7-h3 antitijelo
IL259826A (en)	2018-07-31	Anti-alphabetatisiar antibody
EP2751748A4 (en)	2016-06-15	METHOD AND ARRANGEMENTS FOR IDENTIFYING OBJECTS
GB201103955D0 (en)	2011-04-20	Antibodies
GB201112056D0 (en)	2011-08-31	Antibodies
EP2736330A4 (en)	2015-05-27	COMPOUNDS AND METHODS
EP2768983A4 (en)	2015-06-03	METHODS OF IDENTIFYING MUTATIONS ASSOCIATED WITH DISEASES
ZA201404319B (en)	2015-06-24	Biomarkers and parameters for preeclampsia
EP2747560A4 (en)	2015-02-25	CONNECTIONS AND METHODS
EP2736332A4 (en)	2015-03-18	CONNECTIONS AND METHODS
EP2736329A4 (en)	2015-03-25	COMPOUNDS AND METHODS
EP2637017A4 (en)	2014-10-15	METHOD FOR MEASURING FILLING CAPACITY
EP2700030A4 (en)	2016-05-18	DETERMINATION OF BORE INTEGRITY
ZA201306389B (en)	2015-03-25	Food analogs and methods for making food analogs
EP2791653A4 (en)	2015-09-30	PROCESS FOR OPTIMIZED SCATTEROMETRY
EP2685257A4 (en)	2014-10-01	METHOD OF ANALYSIS
TWI563004B (en)	2016-12-21	Anti-hxcr1 antibody
HK1259180A1 (zh)	2019-11-29	增加成骨細胞功能的方法
IL226429A0 (en)	2013-07-31	An in vitro method for determining the presence of type ii pyrethroids
EP2683996A4 (en)	2015-04-22	SYSTEMS AND PROCESSES FOR FERROUS ENHANCEMENT
EP2757373A4 (en)	2015-07-01	METHOD FOR MEASURING ANTI-WT1 ANTIBODIES
EP2769988A4 (en)	2015-08-05	ANTI-GAP43 ANTIBODY
EP2714074A4 (en)	2015-04-22	ANTIBODIES AGAINST EMR1
GB201104012D0 (en)	2011-04-20	Methods